The Gupta Lab

Researching HIV host pathogen interactions and working towards the elusive cure. The picture shows immunofluorescence of HIV infected monocyte derived macrophages. (Courtesy of Petra Mlcochova)

Researching host-pathogen and drug-pathogen interactions to inform HIV treatment and curative strategies.

The Gupta lab has teams in both London and at the Africa Health Research Institute in Durban South Africa. Our work focuses on two areas:

  • Studying in vitro HIV drug resistance to protease inhibitors and implications for global scale up of antiretroviral therapy.
  • Investigating the details of macrophage infection in clinical isolates. Macrophages are a crucial component of the immune system and a unique cell type in terms of access to sanctuary sites, thus representing a difficult-to-treat reservoir.




News


Dr Petra Mlcochova has again successfully published in Embo J

Mlcochova P, Caswell SJ, Taylor IA, Towers GJ, Gupta RK. DNA damage induced by topoisomerase inhibitors activates SAMHD1 and blocks HIV-1 infection of macrophages. EMBO J. 2017 Oct 30. pii: e201796880. doi: 10.15252/embj.201796880. [Epub ahead of print]


Professor Gupta has published in The Lancet

Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, Kaleebu P , Watera C, Aghokeng A, Mutenda N, Dzangare J, Hone S, Hang ZZ, Garcia J, Garcia Z, Marchorro P, Beteta E, Roman M, Giron A, Hamers R, Inzauke S, Frenkel LM, Chung MH,de Oliveira T, Pillay D, Naidoo K, Kharsany A, Kugathasan R, Cutino T, Hunt G, Avila Rios S, Doherty M, Jordan MR, Bertagnolio S. HIV-1 drug resistance prior to initiation or re-initiation of first-line antiretroviral therapy in low- and middle-income countries – a meta regression analysis. Lancet Infect Dis 2018

Press coverage can be found at the following link in the Daily Mail


Dr Petra Mlcochova's paper has been published in EMBO J
Synopsis of Mlcochova et al, EMBO 2017. Here, we show that macrophages are found in both G0‐ and G1‐like phases, and the latter are permissive to HIV‐1 due to the canonical Raf/MEK/ERK pathway which deactivates SAMHD1 by CDK1‐mediated phosphorylation at T592. Therefore, HIV‐1 does not need to encode a SAMHD1 antagonist.

Petra Mlcochova, Katherine A Sutherland, Sarah A Watters, Cosetta Bertoli, Rob AM de Bruin, Jan Rehwinkel, Stuart J Neil, Gina M Lenzi, Baek Kim, Asim Khwaja, Matthew C Gage, Christiana Georgiou, Alexandra Chittka, Simon Yona, Mahdad Noursadeghi, Greg J Towers, Ravindra K Gupta. A G1‐like state allows HIV‐1 to bypass SAMHD1 restriction in macrophages. The EMBO Journal (2017) e201696025. Published online 25.01.2017

Read the press coverage can be found at the following sites:

On the UCL News page

On the Science Daily website

On the MD Magazine website and

On the United Press International website


Professor Gupta was interviewed by the BRC
Q&A at the BRC

 Gupta lab featured in relaunch of Wellcome Trust Website
Dr Ravi Gupta working in tissue culture featured on the new front psge of the Wellcome Turst website. Image courtesy of Benjamin McMahon, Wellcome Trust

Visiting our Nigerian Colaborators
Dr Kate El Bouzidi and Dr Ravi Gupta with collaborators at the Institute for Human Virology, Nigeria

 The Gupta Lab visited their collaborators in Nigeria at the Institute for Human Virology (IHVN) in April 2016. We are currently hosting Rawlings Datir of IHVN in the Gupta lab and whilst here Rawlings will learn how to construct HIV vectors and perform phenotypic drug resistance assays.


New Grants
Dr Joe Grove, Prof Greg Towers, Dr Ravi Gupta and Dr Clare Jolly celebrate securing Wellcome Trust grants

Ravi has secured a 'Wellcome Senior Research Fellowship in Clinical Science' grant which will fund 5 years of work on 'The genetics and biology of drug resistant HIV'.

Celebrations were held in the UCL Quad to congratulate Ravi along with Dr Joe Grove, Prof Greg Towers and Dr Clare Jolly who all secured Wellcome Trust grants.

Recent Publications


Mlcochova P, Caswell S, Taylor I, Towers GJ, Gupta RK. Topoisomerase inhibitors activate SAMHD1 and block HIV-1 infection in macrophages, In press EMBO J 2017

Collier DA, Iwuji C, Derache A, de Oliveira T, Okesola N, Calmy A, Dabis F, Pillay D, Gupta RK for the ANRS 12249 TasP Study Group. Virological Outcomes of second– line protease inhibitor based treatment for HIV– 1 in a high prevalence rural South African setting – a competing risk prospective cohort analysis. Clin Infect Dis. 2017 Apr 15;64(8):1006-1016

Petra Mlcochova, Katherine A Sutherland, Sarah A Watters, Cosetta Bertoli, Rob AM de Bruin, Jan Rehwinkel, Stuart J Neil, Gina M Lenzi, Baek Kim, Asim Khwaja, Matthew C Gage, Christiana Georgiou, Alexandra Chittka, Simon Yona, Mahdad Noursadeghi, Greg J Towers, Ravindra K Gupta. A G1‐like state allows HIV‐1 to bypass SAMHD1 restriction in macrophages. The EMBO Journal (2017) e201696025. Published online 25.01.2017

Kugathasan R, Collier DA, Haddow LJ, El Bouzidi K, Edwards SG, Cartledge JD, Miller RF, Gupta RK. Diffuse white matter signal abnormalities on MRI are associated with HIV-1 viral escape in the central nervous system among patients with neurological symptoms. Clin Infect Dis. 2017 Apr 15;64(8):1059-106

Goodall R, Dunn DT, Nkurunziza P, Mugarura L, Pattery T, Munderi P, Kityo C, Gilks C, Kaleebu P, Pillay D, Gupta RK on behalf of the DART Virology Group. Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine based first line antiretroviral therapy in sub Saharan Africa. J Antimicrob Chemother. 2017 May 1;72(5):1450-1455

Sutherland KA, Collier DA, Claiborne DT, Prince JL, Deymier MJ, Goldstein RA, Hunter E, Gupta RK. Wide variation in susceptibility of HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency. Scientific Reports 2016; 6: 38153 doi: 10.1038/srep38153

Gregson J, Kaleebu P, Marconi VC, van Vuuren C, Ndembi N, Hamers RL, Kanki P, Hoffmann CJ, Lockman S, Pillay D, de Oliveira T, Clumeck N, Hunt G, Kerschberger B, Shafer RW, Yang C, Raizes E, Kantor R, Gupta RK. Occult drug resistance to thymidine analogues and multidrug resistant HIV-1 following failure of first line tenofovir-based antiretroviral regimens in sub Saharan Africa: a retrospective multi-centre cohort study. Lancet Infect Dis 2016 Epub ahead of print

El Bouzidi K, Collier Dami, Nastouli E, Copas A, Miller RF, Gupta RK. Virologic Efficacy of Protease Inhibitor Monotherapy for HIV-1 in Clinical Practice. Journal of Antimicrobial Chemotherapy 2016 Jul 7. pii: dkw265.

Watters SA, Mlcochova P, Maldarelli F, Goonetilleke N, Pillay D, Gupta RK. Sequential CCR5-Tropic HIV-1 Reactivation From Distinct Cellular Reservoirs Following Perturbation of Elite Control. PLoS One. 2016 Jul 12;11(7):e0158854.

Gregson J, Tang M, Ndembi N, Hamers RL, Rhee SY, Marconi VC, Diero L, Brooks K, Theys, K, Rinke de Wit TF, Arruda M, Garcia F, Monge S, Günthard, HF, Hoffmann, CJ, Kanki PJ, Kumarasamy, N, Kerschberger B, Mor O, Charpentier C, Todesco E, Rokx C, Gras L, Halvas EK, Sunpath H, Di Carlo D, Antinori A, Andreoni M, Latini A, Mussini C, Aghokeng A, Sonnerborg A, Ujjwal Neogi U, Fessel  WJ, Agolory S, Yang C, Blanco JL, Juma JM, Smit, E, Schmidt, D, Watera C, Asio J, Kirungi W, Tostevin A, El-Hay T, Clumeck N, Goedhals D; van Vuuren C, Bester  PA, Sabin C, Mukui I, Santoro MM, Perno CF, Hunt G, Morris L, Camacho  R, de Oliveira T, Pillay D, Schulter E, Akio Murakami-Ogasawara A,  Reyes-Terán G, Romero K, Avila-Rios S, Sirivichayakul, S, Ruxrungtham K, Mekprasan S, Dunn, D, Kaleebu, P, Raizes E, Kantor R, Shafer RW, Gupta RK on behalf of the TenoRes study group. Global epidemiology of drug resistance following failure of WHO recommended first line regimens for adult HIV-1 infection – a multi-centre retrospective cohort study. Lancet Infect Dis 2016. May;16(5):565-75

Power RA, Davaniah S, Derache A, Wilkinson E, Tanser F, Gupta RK, Pillay D, de Oliveira T. Genome-Wide Association Study of HIV Whole Genome Sequences Validated using Drug Resistance. PLoS One. 2016 Sep 27;11(9): e0163746.






Wellcome Trust Logo


The Gupta Lab is funded by the Wellcome Trust Senior Research Fellowship in Clinical Science awarded to Dr Ravi Gupta.



Page last modified on 24 aug 17 22:39 by Jane Lorna Elizabeth Turner